On July 8, Tempus AI declined 5.08% in regular trading, trading at approximately $56.83/share with turnover of $114 million. The sell-off was triggered by Biovica International AB announcing the termination of its collaboration agreement with Tempus AI, explicitly stating the partnership failed to result in any product commercialization or revenue generation.

Biovica said it is realigning its U.S. commercial strategy following the agreement termination, though the move will not affect its San Diego laboratory, U.S. clinical activities, or pharmaceutical services business. Adding to negative sentiment, CEO and Chairman Eric P. Lefkofsky recently sold approximately 126,250 shares of Class A common stock through a Rule 10b5-1 plan at prices ranging from $54.82 to $59.59 per share, with his controlled entities still holding over 24 million shares combined.

Tempus AI is a healthcare technology company that leverages artificial intelligence to advance precision medicine by connecting laboratory results with clinical patient data to enable smarter, more personalized diagnostic testing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)